Dr. Jeffrey Bluestone is the CEO and President of Sonoma Biotherapeutics, a San Francisco and Seattle-based company leveraging the properties of regulatory T cells to create living cell therapies that restore the immune system back to its balanced, fully functioning state. He discusses the company’s research and mission to create therapies that are long-lasting, highly efficacious, and have the potential to slow or prevent autoimmune disease progression and prolong healthy life.
Featured Products and Resources:
- Keep current with the latest in cell therapy research.
- Explore tools and resources for your immunology research at ECI 2021
The Immunology Science Round Up
Linking Neutrophil Death and Lupus – Researchers showed that neutrophils from either lupus-prone mice or patients with systemic lupus erythematosus undergo ferroptosis.
Alterations in Red Blood Cells Contribute to Lupus – Scientists found that lupus may be triggered by a defective process in the development of red blood cells.
TCF-1 Regulates Distinct Treg Cell Functions – Researchers discovered how the transcription factor TCF-1 in Tregs modulates polyps formation in colon cancer.
mRNA Vaccines Produce Strong Immune Response – Scientists showed that mRNA vaccines that protect against COVID-19 produce a robust T cell response.
Image by Steve Babuljak, courtesy of Dr. Jeffrey Bluestone